CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $133.66B, higher than 95% of all stocks globally
- PositionProfit margin is 35%, higher than 95% of its Biotechnology peers (median 8.4%)
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
133.66BUSDvs all stocks (USD)
Trailing P/E
30.72xvs Biotechnology peers
Revenue (TTM)
12.59BUSDvs all stocks (USD)
Profit Margin
35.00%vs Biotechnology peers
Beta
0.3200xvs all stocks
52-Week Change
33.48%vs all stocks
Market Capitalization
133.66BUSDvs all stocks (USD)
Enterprise Value
127.49BUSDvs all stocks (USD)
Trailing P/E
30.72xvs Biotechnology peers
Forward P/E
26.22xvs Biotechnology peers
PEG Ratio
3.86xvs Biotechnology peers
Price to Sales (TTM)
10.60xvs Biotechnology peers
Price to Book (MRQ)
6.59xvs Biotechnology peers
Enterprise to Revenue
10.13xvs Biotechnology peers
Enterprise to EBITDA
25.00xvs Biotechnology peers
Gross Margin
85.33%vs Biotechnology peers
Profit Margin
35.00%vs Biotechnology peers
Operating Margin
38.05%vs Biotechnology peers
Return on Assets (TTM)
11.93%vs Biotechnology peers
Return on Equity (TTM)
23.54%vs Biotechnology peers
Revenue (TTM)
12.59BUSDvs all stocks (USD)
Revenue per Share (TTM)
49.51USDUpdated Sep 28, 2026Quarterly Revenue Growth
12.50%vs Biotechnology peers
Gross Profit (TTM)
6.92BUSDvs all stocks (USD)
EBITDA (TTM)
5.27BUSDvs all stocks (USD)
Net Income (TTM)
4.41BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.50%vs Biotechnology peers
Operating Cash Flow (TTM)
4.29BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
2.63BUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
12.00BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.65BUSDFY2025 · Dec 31, 2025Gross Profit
10.35BUSDFY2025 · Dec 31, 2025Operating Income
4.55BUSDvs all stocks (USD)
Pre-tax Income
4.64BUSDFY2025 · Dec 31, 2025Income Tax Expense
690.00MUSDFY2025 · Dec 31, 2025Net Income
3.95BUSDFY2025 · Dec 31, 2025EBIT
4.66BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
5.25BUSDFY2025 · Dec 31, 2025Research & Development
4.04BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.75BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
490.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.30MUSDFY2025 · Dec 31, 2025EPS (Basic)
15.46USDFY2025 · Dec 31, 2025EPS (Diluted)
15.32USDFY2025 · Dec 31, 2025Basic Shares Outstanding
255.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
255.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
3.95BUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.77BUSDFY2025 · Dec 31, 2025Free Cash Flow
3.33BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.09BUSDFY2025 · Dec 31, 2025Income Tax Paid
1.57BUSDFY2025 · Dec 31, 2025Interest Paid
12.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
3.95BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
209.80MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-510.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
685.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
113.40MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-347.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
36.80MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-375.70MUSDFY2025 · Dec 31, 2025Capital Expenditures
-437.60MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-6.40BUSDFY2025 · Dec 31, 2025Sale of Investments
5.91BUSDFY2025 · Dec 31, 2025Other Investing Activity
-24.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-945.40MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.40MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.39BUSDFY2025 · Dec 31, 2025Other Financing Charges
3.70MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.39BUSDFY2025 · Dec 31, 2025Shares Outstanding
253.35MSharesUpdated Sep 28, 2026Float Shares
252.69MSharesUpdated Sep 28, 2026Shares Short
4.72MSharesUpdated Sep 28, 2026Short Ratio
4.72daysvs all stocks
Short % of Shares Outstanding
2.10%vs all stocks
% Held by Insiders
0.21%vs all stocks
% Held by Institutions
97.96%vs all stocks
Total Cash (MRQ)
7.85BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
30.98USDUpdated Sep 28, 2026Total Debt (MRQ)
1.98BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0977xvs Biotechnology peers
Current Ratio (MRQ)
3.19xvs Biotechnology peers
Book Value per Share (MRQ)
79.92USDUpdated Sep 28, 2026Total Assets
25.64BUSDvs all stocks (USD)
Total Current Assets
11.20BUSDFY2025 · Dec 31, 2025Total Liabilities
6.98BUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.44BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.12BUSDFY2025 · Dec 31, 2025Total Current Liabilities
3.86BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.08BUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.52BUSDFY2025 · Dec 31, 2025Accounts Receivable
2.05BUSDFY2025 · Dec 31, 2025Inventory
1.69BUSDFY2025 · Dec 31, 2025Accounts Payable
461.70MUSDFY2025 · Dec 31, 2025Short-term Debt
77.30MUSDFY2025 · Dec 31, 2025Deferred Revenue
171.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
127.70MUSDFY2025 · Dec 31, 2025Long-term Debt
1.95BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
267.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.50MUSDFY2025 · Dec 31, 2025Retained Earnings
13.56BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
18.67BUSDvs all stocks (USD)
52-Week Low
384.39USDUpdated Sep 28, 202652-Week High
560.25USDUpdated Sep 28, 202652-Week Change
33.48%vs all stocks
Beta
0.3200xvs all stocks
50-Day MA
514.31USDUpdated Sep 28, 2026200-Day MA
471.85USDUpdated Sep 28, 2026Avg 10-Day Volume
1.00MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.01MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
17.15USDUpdated Sep 28, 2026Other Income / Expense
-388.80MUSDFY2025 · Dec 31, 20259 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 35%, higher than 95% of its Biotechnology peers (median 8.4%)Significant
Profit margin: 0.35Industry median: 0.08Industry P95: 0.34Peers compared: 24.00
Financial Health
Altman Z-Score 13.64: safe zoneNotable
Altman Z-Score: 13.64
High structural barrier to entryNotable
Barrier to Entry: 0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $133.66B, higher than 95% of all stocks globallySignificant
Market cap (USD): 133,658,805,934Global P95: 25,554,966,472.502
Levered free cash flow is $2.63B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 2,627,887,616Global P95: 1,207,183,969.279
Revenue is $12.59B, above the global median of $548.88MNotable
Revenue (USD): 12,587,200,512Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule
Bristol-Myers Squibb Company
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medtronic plc
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Stryker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
GSK plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Regeneron Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Games Workshop Group PLC
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Tips Music Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
United States Lime & Minerals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels